Launched in 2006, Western Australia's (WA) Innovators of the Year has celebrated local businesses, government entities and young people that have developed an outstanding innovative product, technology or service for 20 years.
The Community Benefit and Wellbeing Award is awarded to a WA applicant who has developed an outstanding innovative product, technology, process or service that advances social and/or medical wellbeing in the community.
Atherid Therapeutics is the 2026 recipient of the Community Benefit and Wellbeing Award, receiving a cash prize of $30,000 (excl. GST).
Atherid Therapeutics
Erasing arterial blockage: The future of cardiovascular medicine
Our vision is to transform cardiovascular care from lifelong risk management to durable plaque clearance, preventing death and disability. Our first-in-class drug candidate, ATH01, is a short-course treatment delivered through the bloodstream to directly target and clear fatty plaques. ATH01 has the potential to reduce heart attack, stroke and amputation risk, while avoiding invasive procedures such as stents and bypass surgery.
ATH01 uses a naturally occurring human protein that supports healthy cell function but becomes impaired when arterial cells are overloaded with fat. By restoring this function, ATH01 enables cells to metabolise fatty build-up, reducing plaque and improving blood flow. This disease-modifying approach aims to actively reverse established disease, rather than simply slow its progression.
